{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against', 'incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort', 'study. PLoS Med. 2013;1 0:e1001420.', 'Lasserre A, Blaizeau F, Gorwood P, et al. Herpes zoster: a family history and', 'psychological stress-case control study. J Clin Virol. 2012;55:153-157.', 'Liu B, Heywood AE, Reekie J, et al. Risk factors for herpes zoster in a large cohort of', 'unvaccinated older adults: a prospective cohort study. Epidemiol Infect. 2015;16:1-11.', 'Mitnitski AB, Mogilner AJ, Rockwood K. Accumulation of deficits as a proxy measure', 'of aging. Sci World J. 2001; 1: 323-36.', 'Opstelten W, Zuithoff NP, Van Essen GA, et al. Predicting postherpetic neuralgia in', 'elderly primary care patients with herpes zoster: Prospective prognostic study. Pain.', '2007; 132 Suppl 1:S52-59.', 'Oxman MN, Levin MJ, Johnson GR, et al. Shingles Prevention Study Group. A vaccine', 'to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med.', '2005;352:2271-2284.', 'Schmader K, George LK, Burchett BM, et al. Race and stress in the incidence of herpes', 'zoster in older adults. J Am Geriatr Soc. 1998;46:973-977.', 'Scott F, Johnson R, Leedham-Green M, et al. The burden of herpes zoster: A prospective', 'population based study. Vaccine. 2006; 24:1308-1314.', 'Volpi A, Gatti A, Pica F, et al. Clinical and psychosocial correlates of post-herpetic', 'neuralgia. J Med Virol. 2008;80:1646-1652.', 'Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual', 'Life Res. 2001;10:405-13; discussion 415-20.', 'Whitley RJ, Weiss HL, Soong SJ, et al. Herpes zoster: risk categories for persistent pain.', 'J Infect Dis. 1999;179:9-15.', 'Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients', 'with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.', 'Rheumatology (Oxford). 2006;45:1370-1375.', '11-FEB-2019', '46', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'APPENDIX C', 'AMENDMENTS AND ADMINISTRATIVE', 'CHANGES TO THE PROTOCOL', 'GlaxoSmithKline Biologicals SA', 'Vaccines R &D', 'Protocol Administrative Change 1', 'eTrack study number', '204878 (ZOSTER-064)', 'and Abbreviated Title', 'IND number', 'BB-IND-13857', 'Administrative change', 'Administrative change 1', 'number:', 'Administrative change', '27 March 2018', 'date:', 'PPD', 'Co-ordinating author:', 'Scientific Writer', ',', 'Rationale/background for changes:', 'Trademark table updated to include Shingrix', 'Updated background text to include clinical indication', 'Updated study personnel', 'Additional spelling and grammar changes were made throughout for clarification.', 'The Sample EQ-5D questionnaire in Appendix B of the protocol was missing the', 'Visual Analogue Scale (VAS). Images of pages from a sample EQ-5D', 'questionnaire, including the VAS, are now provided to replace the EQ-5D', 'questionnaire text, to better represent the appearance of the EQ-5D questionnaire', 'used in the study.', 'To complement the images of an EQ-5D sample questionnaire in APPENDIX B,', 'images of pages from a sample SF-36 questionnaire are now provided to replace', 'the SF-36 questionnaire text in APPENDIX A, to better represent the appearance', 'of the SF-36 questionnaire used in this study.', 'Amended text has been included in bold italics and deleted text in strikethrough in', 'the following sections:', 'Synopsis', 'Secondary Enppoints', 'Solicited local and general symptoms from ZOSTER-006 and ZOSTER-022:', '11-FEB-2019', '57', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}